Harlan F. Weisman - 18 May 2022 Form 4 Insider Report for TFF Pharmaceuticals, Inc.

Role: Director
Signature: /s/ Harlan F. Weisman, by Kirk Allen Coleman, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 18 May 2022
Net transactions value: +$38,182
Form type: 4
Filing time: 20 May 2022, 17:17:26 UTC
Previous filing: 17 May 2022
Next filing: 06 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TFFP	Common Stock	Purchase	$12,800	+2,500	+33%	$5.12^*	10,000	18 May 2022	Direct
transaction	TFFP	Common Stock	Purchase	$25,382	+4,615	+46%	$5.50^*	14,615	20 May 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported shares were purchased in the open market in multiple transactions at prices ranging from $5.42 to $5.60. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

Content

The reported shares were purchased in the open market in multiple transactions at prices ranging from $5.42 to $5.60. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).